# Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus

Study · id `cardio:ct-nct04707508` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04707508](<https://clinicaltrials.gov/study/NCT04707508>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04707508

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.

## Technical summary

Registry record NCT04707508. Non-randomized; no masking; primary purpose treatment. Start 2017-12-01 (actual); primary completion 2019-01-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 203 participants (enrolled count; ClinicalTrials.gov record NCT04707508, source copy `cardio:ctgov-nct04707508-2021-01-13`, retrieved 2026-10-26)
- Started: 2017-12-01 (actual) (ClinicalTrials.gov record NCT04707508, source copy `cardio:ctgov-nct04707508-2021-01-13`, retrieved 2026-10-26)
- Primary completion: 2019-01-23 (actual) (ClinicalTrials.gov record NCT04707508, source copy `cardio:ctgov-nct04707508-2021-01-13`, retrieved 2026-10-26)
- Completion: 2019-11-29 (actual) (ClinicalTrials.gov record NCT04707508, source copy `cardio:ctgov-nct04707508-2021-01-13`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT04707508, source copy `cardio:ctgov-nct04707508-2021-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04707508-2021-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Valsartan 80 mg and metformin
- Intervention (Drug): Metformin
- Lead sponsor: Nantou Christian Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 07683645508708555d4e2205b65c11fa15fb727ee3a5a31b2d334eb9a602284c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
